BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence into security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company specializing in developing natural and engineered phage cocktails. These cocktails are designed to target and destroy specific bacteria implicated in chronic diseases such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. The company leverages computational and synthetic biology platforms to discover and validate proprietary bacterial targets and customize phage compositions. BiomX also aims to expand into security and defense markets through its X Security & Defense division, identifying and commercializing technologies for national security, emergency response, and critical infrastructure protection. The company operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Drugs Discovery & Development.

Strategic signal

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform. This acquisition signals a strategic pivot and expansion beyond its core microbiome therapies into the security and defense sectors, indicating a diversification of its technological applications and target markets. This move suggests BiomX is leveraging its AI and biological expertise to address broader operational needs, potentially opening new revenue streams and investor interest in its expanded capabilities.

Company Intelligence Q&A

What was a significant recent acquisition by BiomX?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform. This acquisition is aimed at expanding BiomX's presence in security and defense markets.

What was the outcome of the Phase 1b/2a trial for BX004 in cystic fibrosis patients?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

When did BiomX complete patient dosing for its BX004 study?

In October 2023, BiomX announced the completion of patient dosing in Part 2 of the Phase 1b/2a study evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

What was a key strategic partnership for BiomX in 2020?

In September 2020, BiomX entered into a collaboration with Boehringer Ingelheim with the goal of discovering microbiome-based biomarkers for inflammatory bowel disease.

What was a significant corporate event for BiomX in 2019?

In October 2019, Chardan Healthcare Acquisition Corp. completed its merger with BiomX Ltd., leading to BiomX becoming a public company.